Little is known about the prognostic significance of mutations in the IL7R-JAK/STAT pathway in T-ALL [49], and various studies have failed to demonstrate adverse effects for pediatric T-ALL patients harboring IL7R or IL7R/JAK mutations [50–52]. The gene discussed is IL7R; the disease is acute lymphoblastic leukemia.